Our Team

Dan Peterson’s illustrious 55-year career in technology came to a close in 2020 with the sale of Loyale Healthcare, the fourth and final company he founded and led. His entrepreneurial journey included the creation of CASHNet, PBL Associates, and Spectral Systems, each leaving an indelible mark on the industry. Dan’s approach to business and life is rooted in two core principles – harnessing technology responsibly to enhance the lives of customers and contribute positively to the world and believing that sustainable success comes from “doing well by doing good” – benefiting both the people served and the team members who drive that success.

Now based in Santa Fe, NM, Dan remains an active force in the local music and museum community and is passionate about sailing, scuba-diving and flying. He continues to engage his sharp mind through his work with ThinkBio.AI®, demonstrating his ongoing commitment to innovation and progress.

Pradeep Palazhi is a seasoned entrepreneur with over 34 years of experience in diverse sectors including Healthcare, Genomics, Precision Medicine, Synthetic Biology, SaaS, and FinTech. He has founded or played pivotal roles in numerous successful businesses such as Loyale Healthcare, ePAY Healthcare, Saath.Care, HealthVidvan, CASHNet, American HealthNet, and Calsoft. Pradeep’s expertise lies in building large platforms and SaaS products, and managing extensive solutions organizations. He is particularly passionate about creating real solutions to address significant healthcare issues affecting patients’ care and quality of life. His extensive business experience and connections span the US, UK, and India.

Currently, Pradeep serves as Co-Founder and CEO of ThinkBio.Ai®, Inc., focusing on synthetic biology and high-throughput antibody research. Under his leadership, ThinkBio.Ai® leverages AI to drive innovations in the BioTech, Pharma, and Healthcare sectors. His strategic leadership and deep interest in healthcare and biotech have been pivotal in harnessing the transformative power of the BioWave and AI revolution. Pradeep is also a co-founder and CIO of Alstonia.Bio, contributing to a future where technology and biology converge to enhance medical science and patient outcomes.

Sam Santhosh is a visionary entrepreneur with a remarkable 35-year track record of building successful companies across the United States and India. His career spans two distinct phases: the first 20 years in the IT industry, where he founded and took California Software Co Ltd (Calsoft) public in India, and the subsequent 15 years leading the genomic revolution in India. Through his incubator, SciGenom Labs in Kochi and San Francisco, Sam launched multiple companies leveraging Next Generation Sequencing (NGS) and Bioinformatics. His most notable venture, MedGenome, incubated in 2010, raised $120 million from leading venture capital firms and established itself as India’s foremost genomic diagnostics and research company. This success earned Sam the moniker ‘Genome man of India’.

Currently, Sam continues his entrepreneurial journey by incubating startups through SciGenom Labs and promoting genomic research and education via the SciGenom Research Foundation (SGRF), a non-profit trust he established in 2011. His latest passion project involves creating a medicinal plant garden in his hometown of Trichur, Kerala, inspired by the 17th-century work ‘Hortus Malabaricus’ (Garden of Malabar). A mechanical engineer with an MBA from IIM Calcutta, Sam divides his time between San Francisco and Kochi.

Kevin is a seasoned executive leader with extensive experience across Healthcare, Technology, FinTech, and Financial Services industries. His impressive career includes roles as CEO, President, CFO, and Managing Director/Partner, as well as Board of Directors positions. Kevin has a strong track record of building substantial enterprise value through various strategies, including growth capital funding, M&A, organic growth, cash flow enhancements, business model transformation, and turnarounds. His notable achievements include successfully leading Loyale Healthcare as CEO & CFO, where he built thriving SaaS Enterprise Technology and FinTech Payments businesses, securing major healthcare networks as customers and ultimately achieving a successful exit. As CEO & CFO of Paradigm Outcomes, he improved clinical outcomes and customer savings to industry-leading standards, doubling revenue and EBITDA, which led to a $300+ million private equity acquisition.

Throughout his career, Kevin has demonstrated expertise in value acceleration and realization, governance roles, capital readiness and funding, and sell-side M&A. As a Senior Partner at Ernst & Young, he provided consulting and audit services to many of the firm’s largest clients, managing complex projects including large-scale M&A. His industry experience spans Healthcare, Financial Services, Technology, Professional Services, and Life Sciences/Pharma. Kevin’s comprehensive skill set includes strategic advisory consulting, business strategy development, risk management, and executive mentoring. His proven ability to drive growth, optimize operations, and create monetizable value positions him at the forefront of today’s dynamic business landscape.

Michael Evans is a seasoned business leader with over three decades of experience in finance and consulting. He spent 34 years as a Senior Partner at Ernst & Young (EY), where he served as Global Industry Leader for the Real Estate, Hospitality and Construction practice. At EY, Michael held senior management roles in the US and Latin America, helping clients improve financial reporting systems, enhance performance, and streamline operations across various service lines.

Currently, Michael is the Managing Director, Chief Financial Officer, and board member for Newport LLC, a partnership focused on middle market companies’ growth and performance. He also serves on several company boards, including one specializing in Artificial Intelligence. A CPA and attorney, Michael shares his expertise as a lecturer on business planning and succession, and as an author for Forbes.com on private company growth. His diverse background and ongoing engagement with emerging technologies provides him with a unique perspective on business strategy and growth.

As the CTO and founder of Feathersoft Info Solutions Private Limited, Sudhish Chandran is the driving force behind the company’s technology vision and strategy. He spearheads future technology development, focusing on the incubation of emerging technologies, fostering an innovation ecosystem, and creating industry alliances. With over a decade’s experience in delivering software solutions and cloud architecture to niche industries such as Agritech, Fintech, and Biotech, Sudhish is a seasoned executive. His expertise spans Big Data, Hadoop, AI / ML, Application Management, Enterprise Monitoring, IT Infrastructure, and Cloud Computing. Sudhish excels in implementing risk-free, server-less cloud migrations using agile methodologies.

Sudhish is experienced in building high-performance, large-scale real-time systems, microservices, and web applications. He has a stellar track record of assembling highly skilled development teams and delivering innovative solutions tailored to business needs. He is adept at crafting product and technology strategies, leveraging a strong background in consumer internet/mobile and Cloud/SaaS/Enterprise technologies, and establishing world-class technology teams from the ground up. Sudhish leads all aspects of the product lifecycle, from development and quality assurance to presales and customer support, and excels in managing geographically distributed teams.

Dr. Jame Abraham, MD, FACP, is a distinguished medical professional who currently is Chair of Hematology/Medical Oncology at Cleveland Clinic. In this pivotal role, Dr. Abraham is dedicated to recruiting and developing staff while guiding the department's focus on patient access and multidisciplinary care. Alongside these responsibilities, he continues to serve as a Professor of Medicine at Cleveland Clinic Lerner College of Medicine. Prior to assuming his current position, Dr. Abraham made significant contributions as the Director of the Breast Oncology Program at Cleveland Clinic's Taussig Cancer Institute and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program. His leadership in these roles paved the way for his current appointment.

Dr. Abraham's journey in medicine began at Calicut Medical College in Kerala, India, where he earned his medical degree. He then furthered his education and training in the United States, completing a residency at the University of Connecticut. His specialized expertise was honed through fellowships in hematology at the National Heart, Lung, and Blood Institute and in medical oncology at the National Cancer Institute.

Before joining Cleveland Clinic in 2013, Dr. Abraham held several prestigious positions at West Virginia University. There, he served as the Chief of Hematology/Oncology, Professor of Medicine, and was honored as the Bonnie Wells Wilson Distinguished Professor of Breast Cancer Research. As a researcher, Dr. Abraham has made substantial contributions to the understanding and treatment of breast cancer. He has served as the national principal investigator for multiple breast cancer clinical trials, pushing the boundaries of medical knowledge in this critical area. His expertise is further evidenced by his prolific academic output, having published and presented over 200 papers throughout his career. Additionally, Dr. Abraham's influence extends to medical literature as the Founding Editor of The Bethesda Handbook of Clinical Oncology, a valuable resource for oncology professionals.

Dr. Abraham's expertise and leadership are recognized nationally through his involvement in several key committees. He serves as a member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Committee, contributing to the development of guidelines that shape breast cancer care across the country. His role as Vice Chair of NRG Oncology's Research Strategy Committee allows him to influence the direction of oncology research on a broad scale. Furthermore, his membership in NRG Oncology's Breast Cancer Working Committee and his position as Vice Chair of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Research Review Committee demonstrate his deep involvement in shaping the future of breast cancer research and treatment.

Throughout his career, Dr. Jame Abraham has demonstrated an unwavering commitment to advancing breast cancer research and treatment. His combination of clinical expertise, research acumen, and leadership skills makes him an invaluable asset to the field of oncology and a respected figure in the broader oncology community. 

After obtaining undergraduate (1990) and graduate degrees (1996) from Simon Fraser University, Dr. Sidhu worked at Genentech, first as a postdoctoral fellow (1996-1998) and subsequently as a principal investigator. At Genentech, he led the development of synthetic antibody libraries that have proven to be a valuable source of potential therapeutics. Dr. Sidhu is an expert in phage display technology and structure-based combinatorial protein engineering. His research has been instrumental in establishing greatly improved technologies for therapeutic antibody development and engineering of alternative scaffolds.

From 2008 to the present, Dr. Sidhu has led research groups at the interface of industry and academia, through affiliations with the Universities of Toronto and Waterloo. These efforts have led to the engineering of thousands of drug-grade antibodies targeting hundreds of proteins associated with numerous diseases. Many of these have been successfully translated into therapeutic candidates through collaborations with industry partners. Others have enabled the foundation of startup companies, including Dextera, Northern Biologics, Pionyr, Antlera, Aarvik, EPOK, and Axoiya. Most recently, Dr. Sidhu has further strengthened the scope of his industrial efforts through the formation of Simisco Biosciences, a unique platform company that houses a large portfolio of synthetic antibodies and cutting-edge technologies to develop these as therapeutics. Simisco is working with partners across the globe to apply advanced antibody engineering technology to diverse areas of unmet medical needs.  

Dr. Sidhu holds nearly 50 patents and has over 300 peer-reviewed publications. He won the University of Toronto’s Inventor of the Year Award in 2012 and the Protein Society’s Christian B. Anfinsen Award in 2015. He became a Fellow of the National Academy of Inventors in 2020.

Ajikumar “Aji” Parayil is an entrepreneur with more than 20 years of experience in technological innovation and commercialization. He is the Founder and Chief Executive Officer of Manus, the proven BioAlternatives scale-up platform. He invented Manus’ core technology platform at the Massachusetts Institute of Technology (MIT), launched Manus in 2011, and led the successful commercialization of multiple products – BioAlternatives – made through precision fermentation. Notably, Aji has pioneered several novel methods for engineering chemistry using biology to biomanufacture complex natural chemicals. His contributions are reflected in more than 200 U.S. and international granted and pending patents, as well as more than 60 publications in biotechnology and chemical biology. He is an elected fellow of the American Institute of Medical and Bioengineering (AIMBE) and received the Society of Industrial Microbiology’s (SIMB) Raphael Katzen Award in 2021 for enabling the deployment and commercialization of biotechnology to produce fuels and chemicals from renewable resources.

Dr. Akash is a highly accomplished physician with a strong academic foundation, having completed his MBBS from the All India Institute of Medical Sciences (AIIMS) and his MD in General Medicine from the prestigious Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER). These premier institutions reflect his competitive background and drive for excellence. With four years of clinical experience, Dr. Akash has developed expertise in critical care, disease prevention, and multidisciplinary collaboration, working efficiently in high-pressure environments such as ICUs and emergency services. His experience during the COVID-19 pandemic and in various critical care settings has solidified his ability to lead medical teams, manage complex cases, and deliver patient-centered care. 

Beyond his clinical skills, Dr. Akash is deeply passionate about the evolving role of healthcare technology and artificial intelligence in the medical field. He is eager to be at the forefront of this revolution, leveraging these advancements to enhance patient care on a wider scale. His vision is to contribute to innovations that make healthcare more efficient and accessible, ultimately improving outcomes for a broad patient population. With his strong leadership, communication skills, and commitment to staying at the cutting edge of medical practice, Dr. Akash is well positioned to make a significant impact in the health tech sector. 

Dr. Raju holds a medical degree from Government Medical College, Calicut, followed by a Post-Graduate degree in Management from the Tata Institute of Social Sciences (TISS), Mumbai. He began his corporate career in the medical and pharmaceutical sectors, working as a Pharmaceutical Physician for globally recognized Fortune 500 companies like Pfizer, AstraZeneca, Wockhardt, and Menarini. Throughout his tenure, Dr. Raju contributed to various areas, including Medico Marketing, Strategy, and Innovation. He was part of the teams that successfully launched over 50 pharmaceutical products across the Asia Pacific market, including the launch of Forxiga, India's first SGLT2 inhibitor, which became a blockbuster drug within a year of its launch.

With a shift towards Digital Health, Dr. Raju became the Medical Lead for South Asia at Wolters Kluwer, a leading company in clinical decision support systems used by over 2 million doctors across 180 countries. In this role, he collaborated with hospitals and health systems across South Asia to manage the implementation of the advanced system, earning recognition from the CEO for his outstanding collaboration in the Asia-Pacific region.

Dr. Raju later took on the role of Director of Growth at Twin Health, a diabetes digital therapeutics company, where he drove growth strategies. His next move brought him to Dr. Reddy's Laboratories, an Indian multinational pharmaceutical company, where he led the Global Innovation Portfolio focused on Medical Devices and Digital Therapeutics, spearheading the development and launch of groundbreaking innovations to meet the evolving needs of the healthcare sector. Currently, Dr. Raju is consulting and leading the KGDC Project (Kerala Genome Data Centre) under the Kerala Development and Innovation Strategic Council (KDISC). This ₹500 crore government initiative aims to position Kerala as a leader in genomics and bioeconomy.

In addition to his corporate roles, Dr. Raju has authored numerous scientific publications and serves as a mentor and advisor to various startups and health tech investors. He has also been a speaker, moderator, and panelist at numerous scientific and technology conferences. As a Mentor for Femtech Labs in London and an Advisor for the EU-India Innocenter, he actively supports healthcare startups. At ThinkBio.Ai®, Dr. Raju leads enterprise sales for software solutions targeting Life Sciences, Pharma, and Hospitals.

Prior to ThinkBio, Aashind co-founded Saath Care, a consulting firm focused on genomics-driven digital health solutions for chronic illnesses such as oncology and autoimmune disorders. At SciGenom Labs, he further honed his expertise in healthcare innovation, developing the Kerala Genome Data Center and crafting investment strategies in genomics, biologics, and synthetic biology. His role also involved advising healthcare companies on expansion strategies. Earlier, Aashind gained invaluable experience at Areté Advisors—acquired by Bain & Company—where he guided prominent private equity and healthcare clients through market expansion, growth strategy, and due diligence.

Aashind holds a Bachelor’s degree in Chemistry from St. Xavier’s College, Mumbai. Outside of his professional pursuits, he is an avid reader with a keen interest in the intersections of technology, biology, and wellness. Recognised for his contributions to science and education, Aashind remains committed to advancing knowledge and fostering innovation in healthcare.  

Vidhi Malik is the Principal Computational Biologist at ThinkBio.Ai®, where she leads a team of innovative computational biologists in advancing AI-driven bioinformatics research. With a focus on harnessing cutting-edge technologies to analyze complex bioinformatics data, Vidhi’s work transforms data into actionable insights that fuel innovation in genomics and precision healthcare.

Vidhi holds a PhD from IIT Delhi, where her research on molecular targets for cancer therapeutics led to critical advancements in precision oncology, including the development of machine learning models for predicting patient outcomes. As a Postdoctoral Fellow at Brigham and Women’s Hospital and Harvard Medical School, she has conducted pioneering research on Chronic Obstructive Pulmonary Disease (COPD), focusing on the functional genomic responses of lung cells to genetic mutations.

At ThinkBio.Ai®, Vidhi leverages her expertise in SNP-to-Gene mapping, multi-omics integration, single-cell sequencing, molecular modeling, and machine learning, positioning ThinkBio.Ai® at the forefront of bioinformatics and personalized medicine. Her leadership fosters a collaborative environment that pushes the boundaries of computational biology, enabling the transformation of complex bioinformatics data into actionable insights and helping ThinkBio.Ai® deliver meaningful advancements in bioinformatics and patient care.

Shahina is a computational biologist with a strong educational background, holding a Ph.D. in Computational Biology and Bioinformatics from the University of Kerala, along with a Master's and Bachelor's degree in related fields. As part of her PhD program she developed different deep learning models to classify genome sequences of different organisms from their chaos game representation (CGR) images and also studied the effect of different generative adversarial networks and data augmentation techniques on CGR images of biosequences.

With over 7 years of work experience, her expertise lies in Next Generation Sequencing data analysis, machine learning, and deep learning. Professionally, she has held various roles, including Bioinformatician, Bioinformatics Intern at Khalifa University, IT Instructor, and Support Engineer.

She holds certifications in Genomic Variant Analysis & Clinical Interpretation, NIH Clinical Research Training,  ITIL Foundation, Oracle Certified Associate and Microsoft Certified Professional.  Her unique blend of research and industry experience makes her a valuable asset to organizations in bioinformatics, computational biology, and data analytics.

Currently, Dr. Shahina serves as a Computational Biologist at ThinkBio.Ai®, where she works on projects that harness computational techniques to address pressing biological questions.

Dr. Sana Munquad is a computational biologist at ThinkBio.Ai®, where she leverages advanced machine learning and artificial intelligence (AI) techniques to analyze genomic data, advancing the field of personalized medicine. Her work focuses on developing AI-driven models to identify critical biomarkers for predicting drug response, thereby tailoring therapeutic strategies to individual patient profiles.

Dr. Munquad’s academic journey began with a BTech in Biotechnology from Integral University, Lucknow, in 2012, followed by an MTech in Bioinformatics from Maulana Azad National Institute of Technology, Bhopal, in 2015. Awarded the prestigious GATE PhD grant, she completed her PhD in Bioinformatics in 2024 at the National Institute of Technology, Warangal. Her research expertise spans genomic data mining, machine learning model development, and drug target and response prediction.

As high-throughput omics technologies produce vast data, Dr. Munquad’s team at ThinkBio.Ai® focuses on developing computational methods to extract valuable insights, helping to decode complex molecular mechanisms and disease biology. In cancer personalized medicine, her work aims to identify specific biomarkers that predict therapeutic responses, addressing a central challenge in personalized oncology. Through these efforts, Dr. Munquad is at the forefront of using AI to unlock the potential of precision medicine, ultimately aiming to improve patient outcomes with targeted treatment approaches.

As a Scientist in R&D Healthcare and Bioinformatics at ThinkBio.Ai®, Chinju John brings expertise in computational biology and artificial intelligence to advance healthcare solutions. She has a Master's in Computational Biology and a B.Tech in Computer Science and Engineering. With over 9 years of combined experience in academia and industry, Chinju actively contributes to scientific advancement through her work as both an author and reviewer for international journals and conference publications. Her research Interests include Bioinformatics, Deep Learning & Explainable AI.

Chinju’s unique combination of computer science expertise and biological knowledge positions her at the forefront of healthcare innovation at ThinkBio.Ai®, where she applies advanced computational methods to solve complex biological challenges.

Samish Karunalayam is a Chartered Accountant with over 18 years of experience, primarily in the IT industry. He specializes in M&A, Financial Planning & Analysis, Auditing, Accounting & Controllership, Treasury Management, and Stakeholder Management.

Most recently, Samish served as the Head of Finance at Aspire Systems Digital (formerly RapidValue), part of the $200M global IT company Aspire Systems. In this role, he played a pivotal role in several key functions across the group, bringing deep expertise in strategic financial planning, business insight, and ensuring rigorous financial governance and operational controls. He was instrumental in facilitating the acquisition of RapidValue's digital transformation business by Aspire Systems. Before joining Aspire Systems, Samish held a managerial role at Sagitec Solutions, USA, where he oversaw the successful migration from legacy systems to Oracle NetSuite. He also gained valuable experience at Ernst & Young in Audit, Assurance, and Advisory services, further honing his expertise in financial reporting and compliance.

Manoj Krishnan (Kris Manoj) has built a career focused on business innovation and strategic development across multiple sectors. His professional work has primarily centered on creating and scaling business solutions in technology, sustainability, and entrepreneurial ecosystems.

Most recently, at BillionLives Business Initiatives, a social impact startup, he led New Business Initiatives, driving its transformation into an ESG Tech company. He was a founder of Greenturn Idea Factory, a hardware tech startup, where he managed the business and operational aspects. The company was selected for accelerator programs by Facebook India and Dubai Smart City, and received recognition from various organizations including JLL.

His consulting work has spanned multiple domains. At Nuivio Ventures, he worked on identifying innovative business solutions, and at Microsoft Accelerator, he managed a program supporting large startups with an average ARR of $1 million. Recently, he was working with NIC Mauritius, developing a microfinance market entry strategy for the firm that involves designing innovative products, mapping process workflows, and coordinating technology implementation.

Throughout his career, Manoj has demonstrated capabilities in startup ecosystem development, corporate innovation, strategic consulting, and technology-driven business solutions. His work has consistently focused on bridging technological innovation with practical business strategies. Manoj holds an MBA degree from University of Oxford and an engineering degree from College of Engineering, Trivandrum.

As an experienced Healthcare IT professional with more than 25 years in the domain, including a decade in the US Healthcare ITES sector and 15 years focusing on US healthcare products and services, Unnikrishnan’s expertise covers a wide range of areas, including Electronic Medical Records (EMRs), Laboratory Information Systems (LIS), Revenue Cycle Management (RCM), Radiology, and Homecare management applications.

He is an experienced professional with expertise in project and program management, account management, product support, and software implementation. Over the years, he has successfully led large-scale healthcare technology deployments, working closely with cross-functional teams to optimize workflows, improve service delivery, and ensure smooth technology adoption. His leadership has been pivotal in driving customer success, managing complex situations, and keeping teams focused on delivering results. With a bachelor's degree in economics and certifications in ITIL, Six Sigma Green Belt, and Certified Professional Coder (AAPC), along with training in Agile and PRINCE2 methodologies, Unnikrishnan combines strategic insight with practical execution. He is dedicated to developing scalable solutions that address healthcare challenges, improve operations, ensure compliance, and enhance patient care.

Anil Pillai brings over 25 years of experience working with software startups to his role as Senior Vice President of Operations at ThinkBio.Ai®. In this position, he focuses on building high-performing teams in the US and UK to establish ThinkBio.Ai®'s presence in these key regions.

Anil's responsibilities include implementing robust business strategies and operational processes, ensuring regulatory compliance, forging strategic partnerships, and driving business development initiatives. His extensive experience working closely with startup leadership teams will be invaluable as he helps ThinkBio.Ai® execute its long-term growth plans.

Prior to joining ThinkBio.Ai®, Anil held various leadership roles at software startups, including key account manager, VP of Sales, and Head of Operations. He was part of three startups that were later acquired, and he has helped many young companies successfully establish and scale their presence in the US market. Anil is currently also an active advisor to Travancore Analytics Inc., where he mentors the leadership team, manages key client relationships, drives process improvements, and spearheads the expansion of the company's US footprint. Previously, he was the head of operations and part of the leadership team at Rapid Value Solutions Inc., which was acquired by Aspire Systems in 2021.

With his deep understanding of software startup operations and his proven track record of guiding companies through periods of rapid growth, Anil is well-positioned to play a pivotal role in accelerating ThinkBio.Ai®'s expansion into new markets.

Aparna Kochattil is a versatile professional whose career spans product management, business analysis, and marketing across multiple industries. At Thermo Fisher Scientific, she spent over four years as a Product Owner managing multiple scrum teams and overseeing AWS-based cloud and mobile applications. Her experience includes roles at Kaiser Permanente as a Senior Business Analyst, and at Wink Technology Solutions where she led the development of digital magazine platforms and apps.

Earlier in her career, Aparna demonstrated her versatility at Edutech India, where she headed Language Learning Solutions, developing product & go-to-market strategies and managing teams across multiple countries. At the British Council, Chennai, she further honed her strategic communication skills by developing and implementing effective promotional and media campaigns. Her educational background includes an MBA from the University of Madras, a Bachelor of Science degree, and various professional certifications including SAFe POPM and CSPO, reflecting her commitment to continuous learning.

Throughout her career, Aparna has mastered a wide array of skills and tools, from complex project management and cross-functional collaboration to data analysis and stakeholder communication. Her experience combined with her multifaceted background spanning technology, healthcare, media, and education, positions her as a professional who can adapt to diverse business environments and bring valuable cross-industry insights to her work.

Anand Aravind brings over two decades of extensive experience in information technology, with a particular focus on the life sciences, medical devices, pharmaceutical, and healthcare industries. As a trusted client partner and active listener, he excels in leveraging cross-functional team strengths to deliver superior client experiences while driving sustained and profitable growth. His expertise spans presales, sales, program and account management, product development, and operations, making him a versatile leader in the healthcare technology sector.

In his previous role as VP of Operations at Objective Medical Systems, Anand spearheaded the development, sales, and implementation of cutting-edge healthcare solutions. He led initiatives in Electronic Health Records, Population Health Analytics, Remote Patient Monitoring, and AI-driven systems for cardiovascular practices and hospital systems. His leadership ensured compliance with rigorous certification, audit, and clinical quality standards, setting new benchmarks in the industry.

As Director of Sales at NTT Data, Anand demonstrated his exceptional sales leadership by guiding teams in the US Midwest and West regions to achieve over 20% year-over-year revenue growth. His strategic focus on key accounts in the life sciences and medical device sectors, including industry giants like Hospira/Pfizer, Abbott Laboratories, and Stryker Orthopedics, significantly expanded the company's market presence. Anand's unique educational background, combining chemical engineering, an MBA, and advanced training in AI/ML from UT Austin's McCombs School of Business, provides him with a multifaceted perspective that bridges technical innovation with business acumen in the healthcare technology landscape.

Pratheek holds a Master's in Biomedical Engineering (Neuroscience focus) from Duke University NC, USA and an MBA from IIM Ahmedabad, India.

He started his career at Neuroplus as the Product Owner for a EEG-based adaptive learning system for children with learning disabilities such as ADHD, where in addition to charting the product roadmap and strategy, he contributed to the firmware for a prototype device while authoring the code for the user application, data operations, and billing integrations.

Post his MBA, he worked as a marketplace PM at Microsoft, owning the Australian and Canadian markets (then ARR >$200M) and holding responsibility for financial and non-financial KPIs. He worked closely with teams in emerging AI and ML technologies such as BERT and RoBERTa, across the entire ad-auction stack such as selection, relevance, augmentation, etc.

He then joined Saath as the Head of Product, where he helped build and deliver an online companion platform for patients suffering from chronic diseases such as breast cancer and autoimmune diseases. He owned the product roadmap and strategy, as well as tactical implementation steps such as conducting user interviews, developing the UI/UX flows, and writing the feature specifications. 

Most recently, he served a Product and Growth role with Simplismart, an Accel-backed AI infrastructure startup that has developed the fastest inferencing engine globally on NVIDIA chips. His role there was to engineer AI and MLOps solutions for large corporate clients while nurturing the sales pipeline and aiding in developing the long-term product roadmap.